Recent Finacing
Recent Raise
EyeGate Pharma develops ocular therapeutics using its proprietary non‑invasive EyeGate II iontophoretic drug‑delivery system, advancing EGP‑437, a dexamethasone‑derived corticosteroid, through clinical trials for dry eye.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors